Neurometrix ( (NURO) ) has released its Q3 earnings. Here is a breakdown of the information Neurometrix presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
NeuroMetrix, Inc. is a healthcare company specializing in the development and commercialization of neurotechnology devices aimed at addressing chronic pain and diabetes. The company offers wearable and hand-held medical devices supported by proprietary software solutions.
In its Q3 2024 earnings report, NeuroMetrix highlighted a strategic review process aimed at enhancing shareholder value and reported significant changes in its financial metrics. The company has taken steps such as fortifying its board, ceasing common stock sales, reducing workforce, and phasing out older business lines to align with its strategic goals.
The quarter saw a mixed financial performance with Quell revenue increasing by 50% year-over-year, while DPNCheck revenue declined significantly due to changes in Medicare Advantage compensation. Overall, the company’s revenue for Q3 2024 was $0.6 million, a decrease of 51% from the previous year, primarily driven by the decline in DPNCheck sales. Operating expenses were reduced by 25%, resulting in a narrowed net loss of $1.5 million compared to the prior year.
Despite a challenging quarter, NeuroMetrix remains focused on its Quell Fibromyalgia business and is exploring alternative markets for DPNCheck. As of the end of September 2024, the company reported cash and equivalents totaling $14.8 million, indicating a strong liquidity position to support ongoing operations.
Looking forward, NeuroMetrix continues its strategic review process without a set timetable, aiming to identify potential opportunities to boost shareholder value. The company remains committed to navigating market challenges while exploring avenues for growth and profitability.
